Author(s)
Caplan, Arthur L.Keywords
Aborted FetusesAbortion
Abortion on Demand
Allowing to Die
Anencephaly
Animal Organs
Body Parts and Fluids
Brain
Brain Death
Brain Pathology
Cadavers
Child Abuse
Clinical Ethics
Clinical Ethics Committees
Coercion
Conflict of Interest
Consent
Death
Decision Making
Determination of Death
Donors
Ethics
Ethics Committees
Fetal Tissue Donation
Fetuses
Hearts
Hospitals
Human Experimentation
Infants
Moral Policy
Motivation
Murder
Newborns
Organ Donation
Organ Donors
Organ Procurement
Parental Consent
Parents
Primates
Public Policy
Remuneration
Research
Research Ethics
Research Ethics Committees
Resource Allocation
Risks and Benefits
Scarcity
Third Party Consent
Tissue Donation
Tissue Donors
Tissue Transplantation
Transplantation
Full record
Show full item recordOnline Access
http://worldcatlibraries.org/registry/gateway?version=1.0&url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&atitle=Should+Foetuses+or+Infants+Be+Utilized+as+Organ+Donors?&title=Bioethics.+&volume=1&issue=2&pages=119-140&date=1987&au=Caplan,+Arthur+L.http://hdl.handle.net/10822/728191
Abstract
The shortage of organs and tissues for transplantation in infants is particularly severe. Caplan considers the moral and public policy implications of utilizing abortuses and brain dead or anencephalic infants as donors. Arguments favoring their use include the potential benefits for research, benefits to existing infants born with fatal conditions, the ethical cost of relying on primates as sources of organs, and the providing of solace to grieving parents. Arguments against their use include the potential for coercion or conflict of interest in parental decisions about donation, the possibility that abortion may be encouraged, the fact that brain death is difficult to diagnose in infants while organ procurement from anencephalics may be considered murder, and the charge that an increase in infant transplants would be too costly. Caplan concludes that the arguments for using abortuses, anencephalics, and brain dead infants as organ and tissue donors outweigh the arguments against. (KIE abstract)Date
2015-05-05Identifier
oai:repository.library.georgetown.edu:10822/728191Bioethics. 1987 Apr; 1(2): 119-140.
0269-9702
http://worldcatlibraries.org/registry/gateway?version=1.0&url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&atitle=Should+Foetuses+or+Infants+Be+Utilized+as+Organ+Donors?&title=Bioethics.+&volume=1&issue=2&pages=119-140&date=1987&au=Caplan,+Arthur+L.
http://hdl.handle.net/10822/728191
Collections
Related items
Showing items related by title, author, creator and subject.
-
Yemen Civil Society Organizations in Transition : A Mapping and Capacity Assessment of Development-Oriented Civil Society Organizations in Five GovernoratesWorld Bank (Washington, DC, 2013-06)Civil society in Yemen is vibrant and diverse but highly fragmented. It includes independent registered and organized civic groups, less organized local self-help organizations, and charity oriented groups. The first period, from 1950 to 1963, saw a growth in associational activity in the modern enclave of late colonial Aden and within the protectorates of the northern imamate amidst heavy immigration and modernization. A second stage of development took place in the late 1970s and 1980s with very little central control but exceptional affluence thanks to remittances from citizens employed in the Gulf. As the political transition in Yemen continues, there is renewed interest in engaging local Civil Society Organizations (CSOs) in the process of service delivery, decentralization, institution building and in encouraging inclusion and greater citizen participation. The Government has requested that the World Bank update its earlier work on CSOs in Yemen to map and to assess the capacities of present-day, development-oriented CSOs in five governorates. Nearly all of the CSOs that participated in this study were formally registered, non-governmental organizations that were generally independent of tribal or religious affiliation. There is an important opening in Yemen at present to encourage greater social accountability among CSOs and through CSO-Government partnerships. Social accountability includes a growing emphasis on beneficiary engagement in monitoring and assessing government performance as well as service providers, particularly in providing feedback on, and voicing demand for, improved service delivery. Based on this study's findings, it is recommended that the Government reform CSOs-related procedures, including registration, re-licensing, and decentralize avenues for CSO-ministry collaboration on service delivery and standards development to the governorate-level branches of the respective Ministries. Finally, it is recommended that training be made available for Yemeni journalists that cover the work of the country's civic sector or development issues in general.
-
Analiza zjawiska nielegalnego handlu narządami ludzkimi w ujęciu kryminologicznym i prawnymSierant, BartłomiejPraca ukazuje zjawisko handlu narządami ludzkimi, skupiając się głównie na aspekcie kryminologicznym oraz prawnym. Analiza zjawiska handlu narządami wymaga zwrócenia uwagi na jego złożoność, dynamikę rozwoju oraz globalny zasięg. Analiza kryminologiczna wymaga wskazania różnych form handlu narządami obecnego we współczesnym świecie. Istotnym jest także przyjrzenie się rozwiązaniom prawnym, zarówno prawa międzynarodowego jak i krajowego. W rozdziale pierwszym niniejszej pracy skupiam się na problematyce i zasięgu zjawiska, opisuję także rozwój transplantologii jako nauki warunkującej istnienie handlu narządami w obecnej skali i formie. W rozdziale drugim opisuję kryminologiczne aspekty handlu narządami, wraz z rozróżnieniem rodzajów występowania zjawiska. Szerzej opisuję także przypadek grabieży narządów w Chinach. Rozdział trzeci wskazuje na aspekty etyczne handlu narządami. Jest także analizą aktów prawa międzynarodowego, dotyczących handlu narządami, oraz opisuje modele prawa krajowego.
-
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Rosso-Fernández, Clara; Sojo-Dorado, Jesús; Barriga, Angel; Lavín-Alconero, Lucía; Palacios, Zaira; López-Hernández, Inmaculada; Merino, Vicente; Camean, Manuel; Pascual, Alvaro; Rodríguez-Baño, Jesús (BMJ Publishing Group, 2015-12-02)INTRODUCTION Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in desperate situations. It is one of the so-called neglected antibiotics of high potential interest for the future. METHODS AND ANALYSIS The main objective of this project is to demonstrate the clinical non-inferiority of intravenous fosfomycin with regard to meropenem for treating bacteraemic urinary tract infections (UTI) caused by ESBL-EC. This is a 'real practice' multicentre, open-label, phase III randomised controlled trial, designed to compare the clinical and microbiological efficacy, and safety of intravenous fosfomycin (4 g/6 h) and meropenem (1 g/8 h) as targeted therapy for this infection; a change to oral therapy is permitted after 5 days in both arms, in accordance with predetermined options. The study design follows the latest recommendations for designing trials investigating new options for multidrug-resistant bacteria. Secondary objectives include the study of fosfomycin concentrations in plasma and the impact of both drugs on intestinal colonisation by multidrug-resistant Gram-negative bacilli. ETHICS AND DISSEMINATION Ethical approval was obtained from the Andalusian Coordinating Institutional Review Board (IRB) for Biomedical Research (Referral Ethics Committee), which obtained approval from the local ethics committees at all participating sites in Spain (22 sites). Data will be presented at international conferences and published in peer-reviewed journals. DISCUSSION This project is proposed as an initial step in the investigation of an orphan antimicrobial of low cost with high potential as a therapeutic alternative in common infections such as UTI in selected patients. These results may have a major impact on the use of antibiotics and the development of new projects with this drug, whether as monotherapy or combination therapy. TRIAL REGISTRATION NUMBER NCT02142751. EudraCT no: 2013-002922-21. Protocol V.1.1 dated 14 March 2014.